Effect of ambroxol on the concentration of cefotaxime in the bronchoalveolar lavage fluid of rats with pulmonary fibrosis

Chen,Feng; Zhang,Yuan‑Xia; Zhang,Cai‑Qing

doi:10.3892/etm.2014.2112

Effect of ambroxol on the concentration of cefotaxime in the bronchoalveolar lavage fluid of rats with pulmonary fibrosis

Authors:
- Feng Chen
- Yuan‑Xia Zhang
- Cai‑Qing Zhang
View Affiliations

Affiliations: Department of Respiratory Medicine, Shandong Provincial Qianfoshan Hospital, Shandong University, Jinan, Shandong 250014, P.R. China
Published online on: December 8, 2014 https://doi.org/10.3892/etm.2014.2112
Pages: 539-542

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

This study aimed to investigate the effect of ambroxol on the concentration of cefotaxime in the bronchioalveolar lavage fluid of rats with bleomycin‑induced pulmonary fibrosis. A total of 54 Wistar male rats were randomly divided into three groups, namely the normal control group, model group and ambroxol group. On experimental day 0, the rats were intratracheally instilled with bleomycin (5 mg/kg body weight) or sterile saline. The rats in the ambroxol group were then treated with ambroxol (35 mg/kg/day) intraperitoneally. On days 7, 14, 28 after instillation, six rats from each group were sacrificed, bronchial alveolar fluids were recovered and the lungs were collected for histopathological examination following the injection of cefotaxime (600 mg/kg) intravenously. The concentration of cefotaxime in the bronchial alveolar fluids was assayed by a liquid chromatography‑mass spectrometry method. On day 7, the concentration of cefotaxime in the bronchial alveolar fluid of the ambroxol group was lower than that of the model group. On day 14, the concentration of cefotaxime in the bronchial alveolar fluids of the ambroxol group was higher than that of the model group, and the difference between these groups was significant statistically (P<0.001). On day 28, the concentration of cefotaxime in the bronchial alveolar fluids of the ambroxol group decreased sharply, and was lower than that of the model group (P=0.126). These results indicate that ambroxol increased the concentration of cefotaxime in the bronchial alveolar fluids at the primary fibrosis stage.

View Figures

View References

1	American Thoracic Society and European Respiratory Society. Idiopathic pulmonary fibrosis: Diagnosis and treatment. International consensus statement. Am J Respir Crit Care Med. 161:646–664. 2000. View Article : Google Scholar
2	American Thoracic Society and European Respiratory Society. International multidisciplinary consensus classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med. 165:277–304. 2002.
3	Raghu G, Collard HR, Egan JJ, et al: ATS/ERS/JRS/ALAT Committee on Idiopathic Pulmonary Fibrosis: An official ATS/ERS/JRS/ALAT statement: Idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med. 183:788–824. 2011. View Article : Google Scholar : PubMed/NCBI
4	Ley B, Collard HR and King TE Jr: Clinical course and prediction of survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 183:431–440. 2011. View Article : Google Scholar
5	Martinez FJ, Safrin S, Weycker D, et al; IPF Study Group. The clinical course of patients with idiopathic pulmonary fibrosis. Ann Intern Med. 142:963–967. 2005. View Article : Google Scholar : PubMed/NCBI
6	Olson AL, Swigris JJ, Lezotte DC, Norris JM, Wilson CG and Brown KK: Mortality from pulmonary fibrosis increased in the United States from 1992 to 2003. Am J Respir Crit Care Med. 176:277–284. 2007. View Article : Google Scholar : PubMed/NCBI
7	King TE Jr, Albera C, Bradford WZ, et al; INSPIRE Study Group. Effect of interferon gamma-1b on survival in patients with idiopathic pulmonary fibrosis (INSPIRE): a multicentre, randomised, placebo-controlled trial. Lancet. 374:222–228. 2009. View Article : Google Scholar : PubMed/NCBI
8	Hubbard RB, Smith C, Le Jeune I, Gribbin J and Fogarty AW: The association between idiopathic pulmonary fibrosis and vascular disease: a population-based study. Am J Respir Crit Care Med. 178:1257–1261. 2008. View Article : Google Scholar : PubMed/NCBI
9	Spátola J, Poderoso JJ, Wiemeyer JC, et al: Influence of ambroxol on lung tissue penetration of amoxillin. Arzneimittelforschung. 37:965–966. 1987.
10	Gené R, Poderoso JJ, Corazza C, Lasala MB, Wiemeyer JC, Fernández M and Guerreiro RB: Influence of ambroxol on amoxicillin levels in bronchoalveolar lavage fluid. Arzneimittelforschung. 37:967–968. 1987.PubMed/NCBI
11	Wiemeyer JC: Influence of ambroxol on the bronchopulmonary level of antibiotics. Arzneimittelforschung. 31:974–976. 1981.PubMed/NCBI
12	Szapiel SV, Elson NA, Fulmer JD, Hunninghake GW and Crystal RG: Bleomycin-induced interstitial pulmonary disease in the nude, athymic mouse. Am Rev Respir Dis. 120:893–899. 1979.PubMed/NCBI
13	Wang F: Respiratory Tract Infection. Infectious diseases and antimicrobial therapy. 2nd edition. Shanghai Medical University Publishing House; Shanghai, China: pp. 216–223. 2000
14	Morgan EJ and Petty TL: Summary of the National Mucolytic Study. Chest. 97(2 Suppl): 24S–27S. 1990. View Article : Google Scholar : PubMed/NCBI
15	Zhi QM, Yang LT and Sun HC: Protective effect of ambroxol against paraquat-induced pulmonary fibrosis in rats. Intern Med. 50:1879–1887. 2011. View Article : Google Scholar : PubMed/NCBI
16	Pozzi E, Salmona M, Masturzo P, Genghini M, Scelsi M, Spialtini L and Luisetti M: Role of alveolar phospholipids in bleomycin-induced pulmonary fibrosis in the rat. Respiration. 51:23–32. 1987. View Article : Google Scholar : PubMed/NCBI
17	Winsel K: The antioxidative and inflammation inhibiting properties of ambroxol. Pneumologie. 46:461–475. 1992.(In German). PubMed/NCBI
18	Beeh KM, Beier J, Esperester A and Paul LD: Antiinflammatory properties of ambroxol. Eur J Med Res. 13:557–562. 2008.PubMed/NCBI
19	Nowak D, Antczak A, Król M, et al: Antioxidant properties of Ambroxol. Free Radic Biol Med. 16:517–522. 1994. View Article : Google Scholar : PubMed/NCBI
20	Piotrowski WJ, Pietras T, Kurmanowska Z, et al: Effect of paraquat intoxication and ambroxol treatment on hydrogen peroxide production and lipid peroxidation in selected organs of rat. J Appl Toxicol. 16:501–507. 1996. View Article : Google Scholar : PubMed/NCBI
21	Stockley RA, Shaw J and Burnett D: Effect of ambroxol of neutrophil chemotaxis in vitro. Agents Actions. 24:292–296. 1988. View Article : Google Scholar : PubMed/NCBI